
    
      This is a comparative study of patients with a high risk of recurrence of ICD in the first
      episode, treated with Bezlotoxumab (together with standard ICD therapy), with patients with
      first episode of ICD from a paired retrospective cohort (1: 2) using a propensity score.
    
  